Platinum chromium stent performance comparable to cobalt chromium stent at 1 year

American College of Cardiology 60th Annual Scientific Sessions

NEW ORLEANS — Results from the PLATINUM trial indicated that the safety and efficacy of the platinum chromium everolimus-eluting stent were noninferior to those of a cobalt chromium everolimus-eluting stent at 1 year.

Researchers for the trial enrolled 1,530 patients undergoing angioplasty between January and September 2009 and randomly assigned them to receive either a platinum chromium stent (n=768) or a cobalt chromium stent as a control (n=762). The composite primary endpoint consisted of target vessel-related cardiac death, target vessel-related MI or ischemia-driven target lesion revascularization (TLR).

According to the results, the platinum chromium stent was noninferior to the cobalt chromium stent (3.4% vs. 2.9%; P=.001 for noninferiority). There were also no differences between the groups for other safety and efficacy measures, including stent thrombosis (0.4% vs. 0.4%) and TLR (1.9% vs. 1.9%). There were no differences in all-cause mortality between the two groups (3.0% in cobalt chromium group vs. 2.4% in platinum chromium; P=.049).

“A novel platinum chromium everolimus-eluting stent has been developed which has been shown to be noninferior to the predicate cobalt chromium everolimus-eluting stent for target lesion failure, with nonsignificant differences in measures of safety and efficacy demonstrated through 12-month follow-up after PCI,”Gregg W. Stone, MD, professor of medicine and director of CV research at New York Presbyterian Hospital/Columbia University Medical Center, said in a presentation.

Stone pointed out that the study’s limitations included the exclusion of patients with acute MI, chronic total occlusion, bifurcation, left main coronary artery lesions, saphenous vein graft lesions, ostial lesions or lesions with thrombus or excessive tortuosity or calcification. The trial was also not designed to assess differences in deliverability, acute performance or ease of use. – by Eric Raible

Disclosure: Dr. Stone reports receiving consulting fees/honoraria from Medtronic, Boston Scientific and Abbott Vascular, and has served on the Scientific Advisory Boards for Boston Scientific and Abbott Vascular. The study was funded by Boston Scientific.

For more information:

Stone G. LBCT III Session 3014. Presented at: ACC 2011; April 3-5; New Orleans.

Follow CardiologyToday.com on Twitter.